astrazeneca news - Search News

AstraZeneca, AZN

AstraZeneca PLC ADR outperforms market on strong trading day

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top

bovnews · 3m

AstraZeneca PLC (AZN) Stock: Surpassing Expectations in the Market?

AstraZeneca PLC (AZN) stock saw a modest uptick, ending the day at $67.01 which represents a slight increase of $0.43 or 0.65% from the prior close of $66.58. The stock opened at $67.19 and touched a low of $66.

Zacks.com on MSN · 2d

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Astrazeneca (AZN) closed at $66.58, marking a -0.09% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw an upswing of 0.

MarketWatch · 22h

AstraZeneca falls Friday, still outperforms market

AstraZeneca PLC AZN shares inched down 0.05% to £109.82 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,248.49. Supported by world-class markets data from Dow Jones and FactSet,

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

18h

AstraZeneca Files Flurry of Lawsuits to Protect Cancer Treatment Drug

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

3don MSN

J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug

By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...

AstraZeneca PLC Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Against AZN

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

AstraZeneca and Merck drugs set to shake up treatment of liver cancer

Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...

Hosted on MSN4d

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...

AstraZeneca: Uncertainty Ahead, Neutral Rating Confirmed.

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both ...

Vietnam Investment Reviev4d

AstraZeneca joins efforts for universal health coverage

AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.

AstraZeneca’s Promising Pipeline and Strategic Initiatives Drive Buy Recommendation

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

AstraZeneca, AZN

Related topics